U.S. stock-index futures were little distorted, following the Standard & Poor’s 500 Index achieved a record, as talks between Greece and its European creditors broke down.
U.S. stock futures barbed to a offhand day on Wall Street on Tuesday as a stalemate in Greece’s debt talks took a toll on financial markets. Futures for the Dow Jones Industrial Average DJH5, -0.08% dropped down 64 points, or 0.4%, to 17,918, while those for the S&P 500 index SPH5, -0.04% gave up 10.20 points, or 0.5%, to 2,083.30. Futures for the Nasdaq 100 NDH5, -0.01% dropped down 6.75 points, or 0.2%, to 4,370.25.
European stock markets were also lower, with the Stoxx Europe 600 index SXXP, +0.05% down 0.4% at 374.90.
U.S. stock markets are shut on Monday for the Presidents’ Day occasion.
Below is described the comprehensive details of few biotech sector stocks that lands in the bullish zone Friday, following the trend of U.S. Market:
Signal Genetics Inc (NASDAQ:SGNL) gained 122.16%, and closed at $3.91, during the last trading session, soon after a commercial stage molecular diagnostic company, formerly declared that the U.S. Federal Drug Administration (FDA) conditionally approved its proprietary prognostic genetic test, MyPRS (Myeloma Prognostic Risk Signature(R), for use as entry criteria for an forthcoming clinical trial to treat high-risk multiple myeloma (MM) patients sponsored by the University of Arkansas for Medical Sciences (UAMS).
Signal Genetics Inc (NASDAQ:SGNL) a commercial stage molecular diagnostic company, focuses on providing diagnostic services that assists physicians in decision making for the care of patients suffering from cancer.
Cytokinetics, Inc (NASDAQ:CYTK) enhanced 19.88%, and closed at $7.78, during the last trading session, soon after a clinical stage biopharmaceutical company, reported total research and development incomes for the fourth quarter of 2014 were $21.8 million, contrast to $24.3 million during the same period in 2013. The net income for the fourth quarter was $8.4 million, or $0.23 per basic and diluted share. This is contrast to a net income for the same period in 2013, of $6.5 million, or $0.22 per basic share and $0.21 per diluted share. As of December 31, 2014, cash, cash equivalents and investments totaled $83.2 million, which comprises the receipt of $10 million for the sale of ordinary stock to Astellas Pharma Inc., but does not comprise $45.0 million received from Astellas in January 2015. With the recognition of a milestone payment under its partnership agreement with Astellas, the company exceeded its 2014 financial guidance.
Cytokinetics, Inc (NASDAQ:CYTK) a clinical stage biopharmaceutical company, focuses on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.
Biocept Inc (NASDAQ:BIOC) increased 18.49%, and closed at $1.41, during the last trading session, after a cancer diagnostics company, declared the pricing of an underwritten public offering of 8,000,000 shares of its ordinary stock and warrants to purchase up to an aggregate of 8,000,000 shares of its ordinary stock at a combined offering price of $1.25. The warrants will have a per share exercise price of $1.56, are exercisable right away and will expire five years from the date of issuance. The gross proceeds to Biocept from this offering are predictable to be about $10,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses.
Biocept Inc (NASDAQ:BIOC) a cancer diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA tests utilizing a standard blood sample. The company’s tests provide information to oncologists that enable them to select the appropriate treatment for their patients based on detailed data on the characteristics of tumors.
Portola Pharmaceuticals Inc(NASDAQ:PTLA) surged 9.83%, and closed at $34.96, during the last trading session, after a biopharmaceutical company, declared the appointment of Laura Brege and Dennis Fenton, Ph.D., to its board of directors. Ms. Brege serves as president and chief executive officer of Nodality, Inc., a life sciences company focused on innovative personalized medicine. Dr. Fenton is the owner and chief executive officer of Fenton and Associates, a biotechnology-consulting firm.
Portola Pharmaceuticals Inc (NASDAQ:PTLA) a biopharmaceutical company, develops product candidates in the fields of thrombosis and hematology. Its lead compound, Betrixaban, is an oral, once-daily Factor Xa inhibitor in Phase III study for hospital to home prophylaxis of venous thromboembolism (VTE) in acute medically ill patients.
